Sign in Subscribe
Universities and colleges

Telomerase Template Antagonist GRN163L as a Potential Anticancer Agent

Strategic Insights

— 1 min read

Recent research published in the journal Molecular Cancer Therapeutics has shed light on the potential of GRN163L, a novel telomerase template antagonist, as a potential anticancer agent. The study, conducted by E.M. Goldblatt and colleagues at Indiana University's Medical Department, investigated the molecular effects of GRN163L in MDA-MB-231 breast cancer cells. The researchers observed that GRN163L reduced MDA-MB-231 growth rates and altered cell morphology, actin filament organization, and focal adhesion formation in these cells. Furthermore, the combination of GRN163L with paclitaxel significantly inhibited MDA-MB-231 invasive potential and augmented the effects of paclitaxel in breast cancer cell growth in vitro and in vivo.

Key Takeaways:

  • GRN163L, a telomerase template antagonist, has shown efficacy as a potential anticancer agent in reducing MDA-MB-231 growth rates and altering cell morphology and structure.
  • The combination of GRN163L with paclitaxel has demonstrated enhanced anti-tumor activity in vitro and in vivo, suggesting a rationale for its use in treating breast cancer.
  • GRN163L's mechanism of action involves stabilizing telomeres, which prevents apoptosis or cellular senescence, thereby inhibiting tumor growth.
  • The study's results support further exploration of GRN163L as a potential component of combination therapy for breast cancer.
  • Paclitaxel, a microtubule stabilizer, was used in combination with GRN163L to target breast cancer cells and inhibit invasive potential.
  • The study was conducted in vitro and in vivo using MDA-MB-231 breast cancer cells, and the results have implications for the treatment of breast cancer in clinical settings.

Statistics:

  • 85-90% of human tumors display telomerase activity, which stabilizes telomeres and prevents apoptosis or cellular senescence.
  • GRN163L reduced MDA-MB-231 growth rates without a significant effect on breast cancer cell viability within the first 14 days in vitro.
  • Combination therapy with GRN163L and paclitaxel inhibited MDA-MB-231 invasive potential by 80% in vitro.
  • GRN163L's effects on MDA-MB-231 cells were augmented by paclitaxel, resulting in enhanced anti-tumor activity in vitro and in vivo.

Sources:

  • Goldblatt, E.M., et al. "The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel." Molecular Cancer Therapeutics, 2009;8(7):2027-2035.
  • American Association Cancer Research. Molecular Cancer Therapeutics. 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.
  • Indiana University, Medical Department. Department of Medicine and Molecular Genetics, Indianapolis, IN 46202, USA.
  • Cancer Weekly. "Telomerase template antagonist GRN163L shows promise as anticancer agent." 2009.

Read more